TETRACAINE HYDROCHLORIDE- tetracaine hydrochloride solution
Alcon Laboratories, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERIUNIT® safely and effectively. See full prescribing information for Tetracaine Hydrochloride Ophthalmic Solution.

Tetracaine Hydrochloride Ophthalmic Solution 0.5%
STERIUNIT®, topical ophthalmic Initial U.S. Approval: 1965

INDICATIONS AND USAGE
Tetracaine Hydrochloride Ophthalmic Solution 0.5% is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. (1)

DOSAGE AND ADMINISTRATION
One drop topically in the eye(s) as needed. Discard unused portion. (2.1)

DOSAGE FORMS AND STRENGTHS
Sterile ophthalmic solution containing 0.5% tetracaine hydrochloride (3)

CONTRAINDICATIONS
None (4)

WARNINGS AND PRECAUTIONS
Do not use intracamerally since use may damage corneal endothelial cells (5.1)
Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. (5.2)
Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. (5.3)

ADVERSE REACTIONS
Ocular adverse events: stinging, burning, conjunctival redness (6)

To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc., at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 10/2016

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
   2.1 Topical Administration
   2.2 Sterile Field Administration
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS SECTION
5 WARNINGS AND PRECAUTIONS
   5.1 Corneal injury with Intracameral Use
   5.2 Corneal Toxicity
   5.3 Corneal Injury due to Insensitivity
6 ADVERSE REACTIONS
8 USE IN SPECIFIC POPULATIONS
   8.1 Pregnancy
   8.2 Lactation
1 INDICATIONS AND USAGE
Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.

2 DOSAGE AND ADMINISTRATION
2.1 Topical Administration
One drop topically in the eye as needed. Discard unused portion.

2.2 Sterile Field Administration
Open package using standard aseptic technique. The DROP™ TAINER® dispenser may then be allowed to fall upon a sterile surface. The entire outer surface of the DROP™ TAINER® dispenser and its contents are sterile.

3 DOSAGE FORMS AND STRENGTHS
Sterile ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v.

4 CONTRAINDICATIONS SECTION
None.

5 WARNINGS AND PRECAUTIONS
5.1 Corneal injury with Intracameral Use
Not for injection or intraocular use. Do not use intracameraly because use of Tetracaine Hydrochloride Ophthalmic Solution 0.5% may lead to damage of the corneal endothelial cells.

5.2 Corneal Toxicity
Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage.

5.3 Corneal Injury due to Insensitivity
Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.

6 ADVERSE REACTIONS
The following serious ocular adverse reactions are described elsewhere in the labeling:
- Corneal injury with Intracameral Use [See Warnings and Precautions (5.1)]
- Corneal Toxicity [See Warnings and Precautions (5.2)]
- Corneal Injury due to Insensitivity [See Warnings and Precautions (5.3)]

The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Ocular Adverse Reactions
Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort.

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature.

8.2 Lactation
Risk Summary
There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Tetracaine Hydrochloride Ophthalmic Solution 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution 0.5% or from the underlying maternal condition.

8.3 Females and Males of Reproductive Potential
No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution 0.5% on fertility are available.

8.4 Pediatric Use
Safety in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population.

8.5 Geriatric Use
No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients.
10 OVERDOSAGE
Prolonged use of a topical ocular anesthetic including Tetracaine Hydrochloride Ophthalmic Solution 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss. Symptoms related to systemic toxicity consist mainly of effects on the neurologic and cardiovascular systems.

11 DESCRIPTION
Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C_{15}H_{24}N_{2}O_{2} • HCl and it is represented by the chemical structure:

![Chemical Structure of Tetracaine Hydrochloride](image)

Tetracaine hydrochloride is a fine, white, crystalline, odorless powder and has a molecular weight of 300.82. Tetracaine Hydrochloride Ophthalmic Solution 0.5% has a pH of 3.7 to 5.5.

**Active ingredient:** tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine)

**Inactive ingredients:** sodium chloride, sodium acetate trihydrate, acetic acid (to adjust pH approximately 4.5), Water for Injection, USP

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action
Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia.

12.3 Pharmacokinetics
The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride.

Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature.

14 CLINICAL STUDIES
Topical administration of tetracaine hydrochloride ophthalmic solution results in localized temporary anesthesia. The maximum effect is achieved within 10–20 seconds after instillation, with efficacy
last 10–20 minutes. Duration of effect can be extended with repeated dosing. [see Corneal toxicity (5.2) and Overdosage (10)].

16 HOW SUPPLIED/STORAGE AND HANDLING

Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI-UNITS® is supplied as single patient use, 4 mL filled in 4-mL natural medium- or low-density polyethylene plastic DROP-TAINER® dispensers and natural low-density polyethylene tips with white polypropylene caps in a carton of 12. Each sterilized DROP-TAINER® dispenser is packaged in a clear PVC and Tyvek blister. This product does not contain a preservative; discard unused portion.

NDC 0065-0741-14
Storage: Store at 2°C to 25°C (36°F to 77°F). Protect from light. Do not use if solution contains crystals, is cloudy, or discolored.

17 PATIENT COUNSELING INFORMATION

Eye Care Precaution
Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive up to 20 minutes and that care should be taken to avoid accidental injuries.

ALCON®
a Novartis company

Distributed by:
ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
© 2016 Novartis

PRINCIPAL DISPLAY PANEL

NDC 0065-0741-14

Tetracaine Hydrochloride Ophthalmic Solution, 0.5%

STERi-UNITS®

Single Dose DROP-TAINER® dispensers for topical use.
See package insert for directions.

Rx Only

12 x 4mL
STERILE

© 2016 Novartis

Alcon®
A Novartis Company

Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA

Printed in USA
INGREDIENTS: Each mL contains: Active: Tetracaine Hydrochloride 0.5%. (equivalent to tetracaine (0.44%))
Inactive: Sodium Chloride, Sodium Acetate Trihydrate, Acetic Acid (to adjust pH), Water for Injection.

USUAL DOSAGE: One drop topically in the eye(s) as needed. Discard unused portion.

STORAGE: Store at 2°C to 25°C (36°F to 77°F). Protect from Light. Do not use if discolored
TETRACAINE HYDROCHLORIDE
OPHTHALMIC SOLUTION 0.5% 4mL
STERILE UNTIL OPENED PROTECT FROM LIGHT
Rx Only

NDC 0065-0741-14
9013226-0416

Alcon Laboratories, Inc.
Fort Worth, Texas 76134 USA

Alcon®

© 2016 Novartis

TETRACAINE HYDROCHLORIDE
ophtalmic solution
### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
<th>NDC:0065-0741</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>OPHTHALMIC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetracaine Hydrochloride (UNII: 5NF5D4OPCI) (Tetracaine - UNII:0619F35CGV)</td>
<td>Tetracaine Hydrochloride</td>
<td>5 mg in 1 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Chloride (UNII: 451W47IQ8X)</td>
<td></td>
</tr>
<tr>
<td>Sodium Acetate (UNII: 4550K0SC9B)</td>
<td></td>
</tr>
<tr>
<td>Acetic Acid (UNII: Q40Q9N063P)</td>
<td></td>
</tr>
<tr>
<td>Water (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0065-0741-12</td>
<td>12 in 1 CARTON</td>
<td>10/26/2016</td>
<td>10/26/2016</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>2 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:0065-0741-14</td>
<td>12 in 1 CARTON</td>
<td>10/26/2016</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>1 in 1 BLISTER PACK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>4 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA208135</td>
<td>10/26/2016</td>
<td></td>
</tr>
</tbody>
</table>

### Labeler

- **Alcon Laboratories, Inc. (008018525)**

Revised: 12/2019

Alcon Laboratories, Inc.